Journal article
Towards effective and safe thrombolysis and thromboprophylaxis: Preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets
X Wang, J Palasubramaniam, Y Gkanatsas, JD Hohmann, E Westein, R Kanojia, K Alt, D Huang, F Jia, I Ahrens, RL Medcalf, K Peter, CE Hagemeyer
Circulation Research | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
Abstract
RATIONALE:: Fibrinolysis is a valuable alternative for the treatment of myocardial infarction when percutaneous coronary intervention is not available in a timely fashion. For acute ischemic stroke, fibrinolysis is the only treatment option with a very narrow therapeutic window. Clinically approved thrombolytics have significant drawbacks, including bleeding complications. Thus their use is highly restricted, leaving many patients untreated. OBJECTIVE:: We developed a novel targeted fibrinolytic drug that is directed against activated platelets. METHODS AND RESULTS:: We fused single-chain urokinase plasminogen activator (scuPA) to a small recombinant antibody (scFvSCE5), which targets the ac..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by National Heart Foundation
Awarded by Australian Research Council Future Fellowship
Awarded by Australian Research Council
Funding Acknowledgements
This work was funded by National Health and Medical Research Council (NHMRC) project grant 1028145 (to C.E.H. and K.P.) and 1045756 (to R.L.M.); National Heart Foundation Grant-in-Aid G05M2134 (to K.P.) and Career Development Fellowship CR11M6066 (to C.E.H.); and Australian Research Council Future Fellowship FT0992210 (to K.P.) and NHMRC Principle Research Fellowship (to R.L.M.). X.W. was supported by Monash University and Baker IDI Heart and Diabetes Institute; K.A and I.A. were supported by the German Research Foundation. The study was supported in part by the Victorian Government's Operational Infrastructure Support Program.